Time to Clinical Benefit of Dapagliflozin in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial

Muthiah Vaduganathan, Brian L. Claggett, Pardeep Jhund, Rudolf A. De Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S.P. Lam, Felipe Martinez, Sanjiv J. Shah, Akshay S. Desai, Sheila M. Hegde, Daniel Lindholm, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

23 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Time to Clinical Benefit of Dapagliflozin in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science